75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 ...
Study data also showed prolonged progression-free survival with 177 Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich ...
Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data ...
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...
Nektar Therapeutics (NASDAQ:NKTR) released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.
Summit Therapeutics Inc.'s HARMONi study met its PFS endpoint but failed to show statistically significant overall survival, casting doubt on U.S. FDA approval prospects. The FDA has signaled it ...
And how many of them are needed to build a house of cards? Just one — if you're willing to decorate it with decimals and call it science. A global analysis claims plastics are responsible for 13.497% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback